Potential drug interactions in patients with rheumatoid arthritis

Revista Brasileira de Reumatologia

Volumn 51, Issue 1, 2011, Pages 20-39

  Bagatini, Fabíola ^a   Blatt, Carine Raquel ^a   Maliska, Gabriela ^b   Trespash, Gunter Voges ^b   Pereira, Ivânio Alves ^c   Zimmermann, Adriana Fontes ^a   Storb, Bernd Heinrich ^d   Farias, Mareni Rocha ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Antirheumatic drugs; Drug interaction; Polypharmacy; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BENZATHINE PENICILLIN; CHLOROQUINE; CIPROFLOXACIN; COTRIMOXAZOLE; DICLOFENAC; DIPYRONE; DOXYCYCLINE; ETANERCEPT; ETODOLAC; IBUPROFEN; INFLIXIMAB; KETOPROFEN; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NIMESULIDE; OMEPRAZOLE; PANTOPRAZOLE; PHENYLBUTAZONE; TETRACYCLINE; THEOPHYLLINE;

ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; RISK FACTORS; YOUNG ADULT;

EID: 79952976815     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Pinto MRC, Miguel RCC, Rezende GG. Rheumatoid arthritis treatment. Rev Bras Reumatol 2006; 46(3):219-223.
2. Venables PJW, Maini RN. Clinical features of rheumatoid arthritis. In: Greene JM, editor. UpToDate 161a ed. Maini RN: UpToDate; 2008.
3. Senna ER, de Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004; 31:594-7.
4. Organização Mundial de Saúde (OMS), 2009. Disponível em http:// wwwwhoint/chp/topics/rheumatic/en/. [Acesso em 28 de agosto de 2009].
5. th ed. Philadelphia: Elsevier-Saunders 2005; 1043-1100.
6. BRASIL. Portaria SCTIE no 66 de 06 de novembro de 2006. Aprova o Protocolo Clínico e Diretrizes Terapêuticas- AR. Diário Ofcial da União, Poder Executivo, Brasília, DF, 06 de novembro de 2006.
7. Torigoe DY, Laurindo IMM. Artrite Reumatóide e Doenças Cardiovasculares Rev Bras Reum 2006; 46(1):60-66.
8. Secoli SR. Interações medicamentosas: fundamentos para a prática clínica da enfermagem. Rev Esc Enfermagem USP 2001; 35(1):26-32.
9. Souza PM, Santos-Neto LL, Kusano LTE, Pereira MG. Diagnóstico e controle da polifarmácia no idoso. Rev Saúde Pública 2007; 41(6):1049-1053.
10. Steinman MA, Rosenthal GE, Landefeld CS, Bertenthal D, Sen S, Kaboli PJ. Conflicts and concordance between measures of medication prescribing quality. Med Care 2007; 45(1):95-99.
11. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging 2008; 3(2):383-389.
12. Organização Mundial de Saúde (OMS), 2010. WHO Collaborating Centre for Drug Statistics Methodology. Disponível em http://www. whocc.no/atc_ddd_index. [Acesso em 10 de janeiro de 2010].
13. ® Healthcare Series 20: Interactions, 2010. Disponível em http:// periodicoscapesgovbr. [Acesso em 28 de janeiro de 2010].
14. Pincus T, O'dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131(10):768-774.
15. Gabriel SE, Tugwell P, Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002; 61:370-373.
16. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI et al. Combination treatment with lefunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 2009; 38(1):11-14.
17. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1):35-45.
18. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al. The PREMIER Study A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54:26-37.
19. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E et al. Addition of infiximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374(9688):459-466.
20. Ribeiro AQ, Rozenfeld S, Klein CH, Cesar CC, Acurcio FA. Inquérito sobre uso de medicamentos por idosos aposentados, Belo Horizonte, MG. Rev Saúde Pública 2008; 42(4):724-732.
21. Loyola-Filho AI, Uchoa E, Costa-Lima MF. Estudo epidemiológico de base populacional sobre uso de medicamentos entre idosos na Região Metropolitana de Belo Horizonte, Minas Gerais, Brasil. Cad Saúde Pública 2006; 22(12):2657-67.
22. Carvalho MFC. A Polifarmácia em idosos no município de São Paulo- Estudo SABE- Saúde, Bem-estar e Envelhecimento São Paulo- SP [dissertação de mestrado]. São Paulo: Faculdade de Saúde Pública da Universidade de São Paulo; 2007.
23. Flores LM, Mengue SS. Uso de medicamentos por idosos em região do sul do Brasil. Rev Saúde Pública 2005; 39(6):924-929.
24. Prybys KM, Melville K, Hanna J, Gee A, Chyka P. Polypharmacy in the elderly: clinical challenges in emergency practice: part 1 overview, etiology, and drug interactions. Emerg Med Rep 2002; 23(8):145-153.
25. Secoli SR. Polifarmácia: Interações e reações adversas no uso de medicamentos por idosos. Rev Bras Enferm 2010; 63(1):136-140.
26. Harris DE, Schur PH, Maini RN. Overview of the management of rheumatoid arthritis. In: Rose BD, editor. UpToDate 141a ed. Wellesley: UpToDate; 2006.
27. Stockley's IH. Drug interactions. 6a ed. London: Pharmaceutical Press; 2002.
28. Tatro DS, editor. Drug interaction facts. St. Louis: Facts and Comparisons; 2004.
29. Sokka T, Pincus T. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008; 47:1543-1547.
30. Dean R, Nachman J, Lorenzana NA. Possible methotrexate-mezlocillin interaction. Am J Pediatr Hematol Oncol 1992; 14:88-92.
31. Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jiménez NV et al. Pharmacokinetic interaction between high-dose methotrexate and amoxicillin. Ther Drug Monit 1993; 15:375-9.
32. Sathi N, Ackah J, Dawson J. Methotrexate induce neutropenia associated with coprescription of penicillins: serious and under-reported? Rheumatology (Oxford) 2005; 44(8):1051-1055.
33. Sathi N, Dawson J. Methotrexate-induced pancytopenia associated with co-prescription of penicillin and trimethoprim. Clin Rheumatol 2007; 26(1):134-135.
34. Tortajada-Ituren JJ, Ordovas-Baines JP, Liopis-Salvia P, Jiménez-Torres N V. High-dose methotrexate-doxycycline interaction. Ann Pharmacother 1999; 33:804-8.
35. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 17a ed. Hudson: Lexi-Comp; 2008.
36. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumato 1986; 13:440-441.
37. Maricic M, Davis M, Gall EP. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 1986; 29:133-135.
38. Steurer A, Gumpel JM. Methotrexate and trimethoprim: a fatal interaction (letter). Br J Rheumatol 1998; 37:105-106.
39. Groenendal H, Rampen FHJ. Methotrexate and trimethoprim-sulphamethoxazole-a potentially hazardous combination. Clin Exp Dermatol 1990; 15:358-360.
40. Dalle JH, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofoxacin. J Pediatr Hematol Oncol 2002; 24(4):321-322.
41. Chan A, Ko Y, Wong CM. Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profling and Comparison of Two Drug Compendia. Ann Pharmacother 2008; 42(12):1737-1748.
42. Maeda A, Tsuruoka S, Kanai Y, Endou H, Saito K, Miyamoto E et al. Evaluation of the interaction between nonsteroidal anti-infammatory drugs and methotrexate using human organic anion transporter 3-transfected cells Eur J Pharmacol 2008; 596:166-172.
43. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and furbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994; 37:453-456.
44. Vakily M, Amer F, Kukulka MJ, Andhivarothal N. Co administration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 2005; 45(10):1179-1186.
45. Furst DE, Herman RA, Koehnke R, Ericksen N, Hash L, Riggs CE et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990; 79:782-786.
46. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 1991; 34:1514-1520.
47. Reid T, Yuen A, Catolico M, Carlson RW. Impacto of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 1993; 33:82-84.
48. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009; 67(1):44-49.
49. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesúmega L, Giráldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000; 34(9):1024-1037.
50. Glynn-Barnhart AM, Erzurum SC, Leff JA, Martin RJ, Cochran JE, Cott GR et al. Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol 1991; 88:180-186.